Your browser doesn't support javascript.
loading
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Tamura, Hideto; Ishibashi, Mariko; Sunakawa-Kii, Mika; Inokuchi, Koiti.
Afiliação
  • Tamura H; Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Saitama 343-8555, Japan.
  • Ishibashi M; Department of Hematology, Nippon Medical School, Tokyo 113-8603, Japan.
  • Sunakawa-Kii M; Department of Microbiology and Immunology, Nippon Medical School, Tokyo 113-8603, Japan.
  • Inokuchi K; Department of Hematology, Nippon Medical School, Tokyo 113-8603, Japan.
Cancers (Basel) ; 12(4)2020 Apr 10.
Article em En | MEDLINE | ID: mdl-32290052
ABSTRACT
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1+ patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article